

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

O P E
APR 30 2004
PATENT & TRADEMARK

Application No. : 10/781,179
 Applicant : Anthony William Sly
 Filed : February 18, 2004
 TC/A.U. : Not Yet Assigned
 Title : Ophthalmic Fluid

Docket No. : 283702-14-1 (D5053-00031)
 Customer No. : 08933

CERTIFICATE OF MAILING, 37 C.F.R. §1.8(a)	
I certify that this correspondence and the enclosures mentioned therein are being deposited by First Class U.S. Mail with sufficient postage on the date shown below, addressed to Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.	
<i>Richard A. Paikoff</i>	
Richard A. Paikoff, Reg. No. 34,892	Date <u>4/28/04</u>

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL LETTER**

Enclosed herewith is a Supplemental Information Disclosure Statement pursuant to 37 CFR. §1.56 in connection with the above-identified application, which statement is being filed:

Together with the present application.

Before the first Office Action on the merits or three (3) months from the filing date of this application, whichever occurs last. [37 CFR § 1.97(b)]

After the first Office Action on the merits, but before a Final Office Action under §1.113 or Notice of Allowance under §1.311, whichever occurs first. [37 CFR §1.97(c)]. (*Either the fee or certification is provided, as set forth below.*)

After a Final Office Action under §1.113 or Notice of Allowance under §1.311, but prior to or with payment of the Issue Fee. [37 CFR §1.97(d)]. (*The fee and certification are provided, as set forth below.*)

Consistent with Applicant's obligations pursuant to 37 CFR §§1.97 and 1.98, the following requirements have been met:

No separate requirements are needed.

No additional fee is required.

Fee Under 37 CFR § 1.97(c) or 1.97(d)

[] The fee of \$180.00 for submission of an IDS under §1.97(c) as set forth in §1.17(p) accompanies this statement.

Certification Under 37 CFR § 1.97(e)

The undersigned certifies:

[] 1 that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

[] 2 that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

Provision of Copies of References

[X] Pursuant to the order of the Deputy Commissioner dated July 11, 2003, copies of the U.S. references are not enclosed.

[X] A copy of the reference cited is enclosed.

[] A translation of Reference _____ is enclosed herewith and forms a part hereof.

[X] A copy of the European Search Report from a corresponding or related German application is enclosed herewith.

[] A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

Identification of Prior Application(s) In Which Listed Information Was Already Cited And For Which No Copies Are Submitted Or Need Be Submitted

[] This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior U.S. Application No(s). _____, filed _____. The references listed on the attached Form 1449 were cited in the prior application(s) and therefore are not required to be provided in this application.

PATENT

[X] The Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account No. 04-1679.


Respectfully submitted,

Date: 7/28/04

Richard A. Paikoff

Richard A. Paikoff
Registration No. 34,892
DUANE MORRIS LLP
One Liberty Place
Philadelphia, PA 19103-7396
215-979-1853
215-979-1020 fax
mailto: rapaikoff@duanemorris.com

Attorney Docket No.: 283702-14-1 (D5053-00031)



7PTO/SB/08A (10-96)

Patent and Trademark Office: U.S. Department of Commerce

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> Sheet 1 of 1	ATTY. DOCKET NO. 283702-14-1	APPLICATION NO. 10/781,179
	FIRST NAMED APPLICANT Anthony William Sly	EXAMINER
	FILING DATE February 18, 2004	GROUP:

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
AA		4,259,202	Akira, et al.	03/31/81	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	Office	DOCUMENT NUMBER	COUNTRY	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T
AB			WO 98 16217	PCT			

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AC	Harvey, et al., "Identification by Combined Gas Chromatography – Mass Spectrometry of Constituent Long – Chain Fatty Acids and Alcohols from the Meibomian Glands of the Rat and a Comparison with Human Meibomian Lipids", <i>Journal of Chromatography</i> , pp. 253-263 (1987)	
	AD	Copy of European Search Report	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.